Zoledronic acid
- Generic Name
- Zoledronic acid
- Brand Names
- Aclasta, Reclast, Zometa, Zoledronic Acid Accord, Zoledronic acid Actavis, Zoledronic acid medac, Zoledronic acid Teva, Zoledronic Acid Hospira, Zoledronic acid Mylan
- Drug Type
- Small Molecule
- Chemical Formula
- C5H10N2O7P2
- CAS Number
- 118072-93-8
- Unique Ingredient Identifier
- 70HZ18PH24
- Background
Zoledronic acid, or CGP 42'446, is a third generation, nitrogen containing bisphosphonate similar to ibandronic acid, minodronic acid, and risedronic acid. Zoledronic acid is used to treat and prevent multiple forms of osteoporosis, hypercalcemia of malignancy, multiple myeloma, bone metastases from solid tumors, and Paget’s disease of bone. Zoledronic acid was first described in the literature in 1994.
Zoledronic acid was granted FDA approval on 20 August 2001.
- Indication
Zoledronic acid is indicated to treat hypercalcemia of malignancy, multiple myeloma, bone metastases from solid tumors, osteoporosis in men and postmenopausal women, glucocorticoid induced osteoporosis, and Paget's disease of bone in men and women. Zoledronic acid is also indicated for the prevention of osteoporosis in post menopausal women and glucocorticoid induced osteoporosis.
- Associated Conditions
- Bone Metastases, Hypercalcemia of Malignancy, Multiple Myeloma (MM), Osteoporosis, Osteoporosis caused by Glucocorticoid Treatment, Paget's Disease of Bone, Paget’s Disease
- Associated Therapies
- Bone Mineral Density
Zoledronate, Vitamin D, and Calcium With or Without Strontium 89 or Samarium 153 in Preventing or Delaying Bone Problems in Patients With Bone Metastases From Prostate Cancer, Lung Cancer, or Breast Cancer
- First Posted Date
- 2006-08-17
- Last Posted Date
- 2019-06-14
- Lead Sponsor
- Radiation Therapy Oncology Group
- Target Recruit Count
- 261
- Registration Number
- NCT00365105
- Locations
- 🇺🇸
Providence Cancer Center at Providence Hospital, Mobile, Alabama, United States
🇺🇸Radiation Oncology Center - Roseville, Roseville, California, United States
🇺🇸Robert and Beverly Lewis Family Cancer Care Center at Pomona Valley Hospital Medical Center, Pomona, California, United States
Intervenous (IV) Zoledronic Acid After Forteo in Postmenopausal Women
- First Posted Date
- 2006-08-08
- Last Posted Date
- 2017-04-21
- Lead Sponsor
- The Cleveland Clinic
- Target Recruit Count
- 35
- Registration Number
- NCT00361595
- Locations
- 🇺🇸
The Cleveland Clinic Foundation, Cleveland, Ohio, United States
Effect of Zoledronic Acid on Chemotherapy Induced Bone Loss
- Conditions
- Interventions
- First Posted Date
- 2006-07-17
- Last Posted Date
- 2013-07-02
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 135
- Registration Number
- NCT00352846
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Evaluation of Efficacy of Zoledronic Acid in Patients With Haemoglobin Syndromes (Thalassemia and Sicle Cell Anaemia) and Risk of Skeletal Events
- Conditions
- First Posted Date
- 2006-06-29
- Last Posted Date
- 2012-05-01
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 60
- Registration Number
- NCT00346242
- Locations
- 🇬🇷
Novartis Investigative Site, Athens, Greece
Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2006-06-06
- Last Posted Date
- 2017-02-07
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 411
- Registration Number
- NCT00334139
- Locations
- 🇩🇪
Novartis Investigative Site, Ulm, Germany
Safety/Efficacy of Letrozole Monotherapy or in Combination With Zoledronic Acid as Extended Adjuvant Treatment of Postmenopausal Patients With Primary Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2006-06-02
- Last Posted Date
- 2011-11-16
- Lead Sponsor
- Novartis
- Target Recruit Count
- 83
- Registration Number
- NCT00332709
- Locations
- 🇩🇪
Novaertis Investigative Site, Hamein, Germany
🇩🇪Novartis Investigative Site, Witten, Germany
A Study of Zoledronic Acid in the Prevention of Cancer Therapy-induced Bone Loss
- Conditions
- Interventions
- First Posted Date
- 2006-06-02
- Last Posted Date
- 2014-11-25
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 11
- Registration Number
- NCT00333229
- Locations
- 🇩🇪
Novartis Investigative Site, Marburg, Germany
Study of Denosumab vs. Zoledronic Acid to Treat Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma.
- First Posted Date
- 2006-05-29
- Last Posted Date
- 2022-11-07
- Lead Sponsor
- Amgen
- Target Recruit Count
- 1779
- Registration Number
- NCT00330759
Ibandronate or Zoledronate in Treating Patients With Newly Diagnosed Bone Metastases From Breast Cancer
- First Posted Date
- 2006-05-17
- Last Posted Date
- 2013-03-13
- Lead Sponsor
- Wales Cancer Trials Unit
- Target Recruit Count
- 1404
- Registration Number
- NCT00326820
- Locations
- 🇬🇧
St. Mary's Hospital, Newport, England, United Kingdom
🇬🇧Dorset Cancer Centre, Poole Dorset, England, United Kingdom
🇬🇧Alexandra Healthcare NHS, Redditch, Worcestershire, England, United Kingdom
Study of Denosumab vs. Zoledronic Acid to Treat Bone Metastases in Men With Hormone-refractory Prostate Cancer
- First Posted Date
- 2006-05-04
- Last Posted Date
- 2018-08-29
- Lead Sponsor
- Amgen
- Target Recruit Count
- 1904
- Registration Number
- NCT00321620
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.